Molecular and Clinical Features of Hepatocellular Carcinoma in Patients with HBV-HDV Infection

References

• Petrick JL, Florio AA, Znaor A, et al. International trends in hepatocellular carcinoma incidence, 1978–2012. Int J Cancer. 2020;147(2):317–330. PMID: 31597196 PMCID: PMC7470451. doi:10.1002/ijc.32723
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. PMID: 33479224. doi:10.1038/s41572-020-00240-3
   PubMed Web of Science ®Google Scholar
• Anthony PP. Hepatocellular carcinoma: an overview. Histopathology. 2001;39(2):109–118. PMID: 11493326. doi:10.1046/j.1365-2559.2001.01188.x
   PubMed Web of Science ®Google Scholar
• Ringelhan M, Pfister D, O’Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19(3):222–232. PMID: 29379119. doi:10.1038/s41590-018-0044-z
   PubMed Web of Science ®Google Scholar
• Beste LA, Leipertz SL, Green PK, Dominitz JA, Ross D, Ioannou GN. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001–2013. Gastroenterology. 2015;149(6):1471–1482.e5; quiz e17–e18. doi:10.1053/j.gastro.2015.07.056
   Web of Science ®Google Scholar
• Romeo R, Petruzziello A, Pecheur EI, et al. Hepatitis delta virus and hepatocellular carcinoma: an update. Epidemiol Infect. 2018;146(13):1612–1618. PMID: 29991359 PMCID: PMC9507952. doi:10.1017/S0950268818001942
   PubMed Web of Science ®Google Scholar
• McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73(Suppl1):4–13. PMID: 32319693 PMCID: PMC7577946. doi:10.1002/hep.31288
   PubMed Web of Science ®Google Scholar
• Ioannou GN. Epidemiology and risk-stratification of NAFLD-associated HCC. J Hepatol. 2021;75(6):1476–1484. PMID: 34453963. doi:10.1016/j.jhep.2021.08.012
   PubMed Web of Science ®Google Scholar
• Akinyemiju T, Abera S, Ahmed M, et al.; Global Burden of Disease Liver Cancer Collaboration. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the Global, Regional, and National Level: results From the Global Burden of Disease Study 2015. JAMA Oncol. 2017;3(12):1683–1691. PMID: 28983565 PMCID: PMC5824275. doi:10.1001/jamaoncol.2017.3055
   PubMed Web of Science ®Google Scholar
• Liang TJ. Hepatitis B: the virus and disease. Hepatology. 2009;49(5 Suppl):S13–S21. PMID: 19399811 PMCID: PMC2809016. doi:10.1002/hep.22881
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address: [email protected]; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. PMID: 28427875. doi:10.1016/j.jhep.2017.03.021
   PubMed Web of Science ®Google Scholar
• Stockdale AJ, Kreuels B, Henrion MYR, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020;73(3):523–532. PMID: 32335166 PMCID: PMC7438974. doi:10.1016/j.jhep.2020.04.008
   PubMed Web of Science ®Google Scholar
• Bonino F, Heermann KH, Rizzetto M, Gerlich WH. Hepatitis delta virus: protein composition of delta antigen and its hepatitis B virus-derived envelope. J Virol. 1986;58(3):945–950. PMID: 3701932 PMCID: PMC253003. doi:10.1128/JVI.58.3.945-950.1986
   PubMed Web of Science ®Google Scholar
• Taylor JM. Hepatitis delta virus. Virology. 2006;344(1):71–76. PMID: 16364738. doi:10.1016/j.virol.2005.09.033
   PubMed Web of Science ®Google Scholar
• Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011;378(9785):73–85. PMID: 21511329. doi:10.1016/S0140-6736(10)61931-9
   PubMed Web of Science ®Google Scholar
• Nisini R, Paroli M, Accapezzato D, et al. Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles. J Virol. 1997;71(3):2241–2251. PMID: 9032359 PMCID: PMC191332. doi:10.1128/JVI.71.3.2241-2251.1997
   PubMed Web of Science ®Google Scholar
• Liao B, Zhang F, Lin S, et al. Epidemiological, clinical and histological characteristics of HBV/HDV co-infection: a retrospective cross-sectional study in Guangdong, China. PLoS One. 2014;9(12):e115888. PMID: 25532128 PMCID: PMC4274124. doi:10.1371/journal.pone.0115888
   PubMed Web of Science ®Google Scholar
• Govindarajan S, De Cock KM, Redeker AG. Natural course of delta superinfection in chronic hepatitis B virus-infected patients: histopathologic study with multiple liver biopsies. Hepatology. 1986;6(4):640–644. PMID: 3525368. doi:10.1002/hep.1840060415
   PubMed Web of Science ®Google Scholar
• Roingeard P, Dubois F, Marcellin P, et al. Persistent delta antigenaemia in chronic delta hepatitis and its relation with human immunodeficiency virus infection. J Med Virol. 1992;38(3):191–194. PMID: 1287132. doi:10.1002/jmv.1890380307
   PubMed Web of Science ®Google Scholar
• Bichko V, Netter HJ, Wu TT, Taylor J. Pathogenesis associated with replication of hepatitis delta virus. Infect Agents Dis. 1994;3(2–3):94–97. PMID: 7812659.
   PubMedGoogle Scholar
• Guilhot S, Huang SN, Xia YP, La Monica N, Lai MM, Chisari FV. Expression of the hepatitis delta virus large and small antigens in transgenic mice. J Virol. 1994;68(2):1052–1058. PMID: 8289334 PMCID: PMC236543. doi:10.1128/JVI.68.2.1052-1058.1994
   PubMed Web of Science ®Google Scholar
• Rizzetto M. Hepatitis D: thirty years after. J Hepatol. 2009;50(5):1043–1050. PMID: 19285743. doi:10.1016/j.jhep.2009.01.004
   PubMed Web of Science ®Google Scholar
• Buti M, Homs M, Rodriguez-Frias F, et al. Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study. J Viral Hepat. 2011;18(6):434–442. PMID: 20546496. doi:10.1111/j.1365-2893.2010.01324.x
   PubMed Web of Science ®Google Scholar
• Grabowski J, Wedemeyer H. Hepatitis delta: immunopathogenesis and clinical challenges. Dig Dis. 2010;28(1):133–138. PMID: 20460901. doi:10.1159/000282076
   PubMed Web of Science ®Google Scholar
• Saracco G, Rosina F, Brunetto MR, et al. Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection. J Hepatol. 1987;(3):274–281. PMID: 3429834. doi:10.1016/s0168-8278(87)80032-6
   PubMed Web of Science ®Google Scholar
• Romeo R, Del Ninno E, Rumi M, et al. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009;136(5):1629–1638. PMID: 19208358. doi:10.1053/j.gastro.2009.01.052
   PubMed Web of Science ®Google Scholar
• Humans, I.W.G.o.t.E.o.C.R.t. Hepatitis Viruses. Vol. 59. World Health Organization; 1994.
   Google Scholar
• Cross TJ, Rizzi P, Horner M, et al. The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J Med Virol. 2008;80(2):277–282. PMID: 18098143. doi:10.1002/jmv.21078
   PubMed Web of Science ®Google Scholar
• Manesis EK, Vourli G, Dalekos G, et al. Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. J Hepatol. 2013;59(5):949–956. PMID: 23850875. doi:10.1016/j.jhep.2013.07.005
   PubMed Web of Science ®Google Scholar
• Brancaccio G, Fasano M, Grossi A, Santantonio TA, Gaeta GB. Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir. Aliment Pharmacol Ther. 2019;49(8):1071–1076. PMID: 30793345. doi:10.1111/apt.15188
   PubMed Web of Science ®Google Scholar
• Fattovich G, Giustina G, Christensen E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut. 2000;46(3):420–426. PMID: 10673308 PMCID: PMC1727859. doi:10.1136/gut.46.3.420
   PubMed Web of Science ®Google Scholar
• Amougou MA, Noah DN, Moundipa PF, Pineau P, Njouom R. A prominent role of hepatitis D virus in liver cancers documented in Central Africa. BMC Infect Dis. 2016;16(1):647. PMID: 27821080 PMCID: PMC5100184. doi:10.1186/s12879-016-1992-2
   PubMedGoogle Scholar
• Romeo R, Foglieni B, Casazza G, Spreafico M, Colombo M, Prati D. High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta. PLoS One. 2014;9(3):e92062. PMID: 24658127 PMCID: PMC3962389. doi:10.1371/journal.pone.0092062
   PubMed Web of Science ®Google Scholar
• Chang TE, Su CW, Huang YS, Huang YH, Hou MC, Wu JC. Hepatitis D virus dual infection increased the risk of hepatocellular carcinoma compared with hepatitis B virus mono infection: a meta-analysis. J Chin Med Assoc. 2022;85(1):30–41. PMID: 35006125. doi:10.1097/JCMA.0000000000000606
   PubMed Web of Science ®Google Scholar
• Alfaiate D, Clément S, Gomes D, Goossens N, Negro F. Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. J Hepatol. 2020;73(3):533–539. PMID: 32151618. doi:10.1016/j.jhep.2020.02.030
   PubMed Web of Science ®Google Scholar
• Tarocchi M, Polvani S, Marroncini G, Galli A. Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis. World J Gastroenterol. 2014;20(33):11630–11640. PMID: 25206269 PMCID: PMC4155355. doi:10.3748/wjg.v20.i33.11630
   PubMed Web of Science ®Google Scholar
• He G, Karin M. NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res. 2011;21(1):159–168. PMID: 21187858 PMCID: PMC3193410. doi:10.1038/cr.2010.183
   PubMed Web of Science ®Google Scholar
• Lawal G, Xiao Y, Rahnemai-Azar AA, et al. The immunology of hepatocellular carcinoma. Vaccines. 2021;9(10):1184. PMID: 34696292 PMCID: PMC8538643. doi:10.3390/vaccines9101184
   Web of Science ®Google Scholar
• He G, Dhar D, Nakagawa H, et al. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell. 2013;155(2):384–396. PMID: 24120137 PMCID: PMC4015514. doi:10.1016/j.cell.2013.09.031
   PubMed Web of Science ®Google Scholar
• Yang YM, Kim SY, Seki E. Inflammation and liver cancer: molecular mechanisms and therapeutic targets. Semin Liver Dis. 2019;39(1):26–42. PMID: 30809789 PMCID: PMC6616367. doi:10.1055/s-0038-1676806
   PubMed Web of Science ®Google Scholar
• Jiang R, Tan Z, Deng L, et al. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology. 2011;54(3):900–909. PMID: 21674558. doi:10.1002/hep.24486
   PubMed Web of Science ®Google Scholar
• Lan YT, Fan XP, Fan YC, Zhao J, Wang K. Change in the Treg/Th17 cell imbalance in hepatocellular carcinoma patients and its clinical value. Medicine. 2017;96(32):e7704. PMID: 28796055 PMCID: PMC5556221. doi:10.1097/MD.0000000000007704
   PubMed Web of Science ®Google Scholar
• Yeung OW, Lo CM, Ling CC, et al. Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma. J Hepatol. 2015;62(3):607–616. PMID: 25450711. doi:10.1016/j.jhep.2014.10.029
   PubMed Web of Science ®Google Scholar
• Chen J, Gingold JA, Su X. Immunomodulatory TGF-β signaling in hepatocellular carcinoma. Trends Mol Med. 2019;25(11):1010–1023. PMID: 31353124. doi:10.1016/j.molmed.2019.06.007
   PubMed Web of Science ®Google Scholar
• Blank CU, Haining WN, Held W, et al. Defining ‘T cell exhaustion’. Nat Rev Immunol. 2019;19(11):665–674. PMID: 31570879 PMCID: PMC7286441. doi:10.1038/s41577-019-0221-9
   PubMed Web of Science ®Google Scholar
• Fisicaro P, Barili V, Rossi M, et al. Pathogenetic mechanisms of T cell dysfunction in chronic HBV infection and related therapeutic approaches. Front Immunol. 2020;11:849. PMID: 32477347 PMCID: PMC7235343. doi:10.3389/fimmu.2020.00849
   PubMed Web of Science ®Google Scholar
• An Y, Gao S, Zhao WC, et al. Transforming growth factor-β and peripheral regulatory cells are negatively correlated with the overall survival of hepatocellular carcinoma. World J Gastroenterol. 2018;24(25):2733–2740. PMID: 29991878 PMCID: PMC6034152. doi:10.3748/wjg.v24.i25.2733
   PubMed Web of Science ®Google Scholar
• Achyut BR, Yang L. Transforming growth factor-β in the gastrointestinal and hepatic tumor microenvironment. Gastroenterology. 2011;141(4):1167–1178. PMID: 21839702 PMCID: PMC6644047. doi:10.1053/j.gastro.2011.07.048
   PubMed Web of Science ®Google Scholar
• Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2015;21(4):687–692. PMID: 25501578 PMCID: PMC4334715. doi:10.1158/1078-0432.CCR-14-1860
   PubMed Web of Science ®Google Scholar
• Zhang HH, Mei MH, Fei R, et al. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses. J Viral Hepat. 2010;17(Suppl 1):34–43. PMID: 20586932. doi:10.1111/j.1365-2893.2010.01269.x
   PubMedGoogle Scholar
• Yang P, Li QJ, Feng Y, et al. TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell. 2012;22(3):291–303. PMID: 22975373 PMCID: PMC3443566. doi:10.1016/j.ccr.2012.07.023
   PubMed Web of Science ®Google Scholar
• Ringelhan M, O’Connor T, Protzer U, Heikenwalder M. The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets. J Pathol. 2015;235(2):355–367. PMID: 25196558. doi:10.1002/path.4434
   PubMed Web of Science ®Google Scholar
• Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut. 2015;64(12):1972–1984. PMID: 26048673. doi:10.1136/gutjnl-2015-309809
   PubMed Web of Science ®Google Scholar
• Sung WK, Zheng H, Li S, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet. 2012;44(7):765–769. PMID: 22634754. doi:10.1038/ng.2295
   PubMed Web of Science ®Google Scholar
• Chemin I, Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett. 2009;286(1):52–59. PMID: 19147276. doi:10.1016/j.canlet.2008.12.003
   PubMed Web of Science ®Google Scholar
• Hwang GY, Lin CY, Huang LM, et al. Detection of the hepatitis B virus X protein (HBx) antigen and anti-HBx antibodies in cases of human hepatocellular carcinoma. J Clin Microbiol. 2003;41(12):5598–5660. PMID: 14662947 PMCID: PMC309044. doi:10.1128/JCM.41.12.5598-5603.2003
   PubMed Web of Science ®Google Scholar
• Kuo TC, Chao CC. Hepatitis B virus X protein prevents apoptosis of hepatocellular carcinoma cells by upregulating SATB1 and HURP expression. Biochem Pharmacol. 2010;80(7):1093–1102. PMID: 20541537. doi:10.1016/j.bcp.2010.06.003
   PubMed Web of Science ®Google Scholar
• Hsieh A, Kim HS, Lim SO, Yu DY, Jung G. Hepatitis B viral X protein interacts with tumor suppressor adenomatous polyposis coli to activate Wnt/β-catenin signaling. Cancer Lett. 2011;300(2):162–172. PMID: 20971552. doi:10.1016/j.canlet.2010.09.018
   PubMed Web of Science ®Google Scholar
• Chan C, Wang Y, Chow PK, Chung AY, Ooi LL, Lee CG. Altered binding site selection of p53 transcription cassettes by hepatitis B virus X protein. Mol Cell Biol. 2013;33(3):485–497. PMID: 23149944 PMCID: PMC3554210. doi:10.1128/MCB.01189-12
   PubMed Web of Science ®Google Scholar
• Clippinger AJ, Bouchard MJ. Hepatitis B virus HBx protein localizes to mitochondria in primary rat hepatocytes and modulates mitochondrial membrane potential. J Virol. 2008;82(14):6798–6811. PMID: 18448529 PMCID: PMC2446973. doi:10.1128/JVI.00154-08
   PubMed Web of Science ®Google Scholar
• Yang B, Bouchard MJ. The hepatitis B virus X protein elevates cytosolic calcium signals by modulating mitochondrial calcium uptake. J Virol. 2012;86(1):313–327. PMID: 22031934 PMCID: PMC3255901. doi:10.1128/JVI.06442-11
   PubMed Web of Science ®Google Scholar
• Sosa V, Moliné T, Somoza R, Paciucci R, Kondoh H, LLeonart ME. Oxidative stress and cancer: an overview. Ageing Res Rev. 2013;12(1):376–390. PMID: 23123177. doi:10.1016/j.arr.2012.10.004
   PubMed Web of Science ®Google Scholar
• Jin Y, Wu D, Yang W, et al. Hepatitis B virus x protein induces epithelial-mesenchymal transition of hepatocellular carcinoma cells by regulating long non-coding RNA. Virol J. 2017;14(1):238. PMID: 29258558 PMCID: PMC5735895. doi:10.1186/s12985-017-0903-5
   PubMedGoogle Scholar
• Wen Y, Golubkov VS, Strongin AY, Jiang W, Reed JC. Interaction of hepatitis B viral oncoprotein with cellular target HBXIP dysregulates centrosome dynamics and mitotic spindle formation. J Biol Chem. 2008;283(5):2793–2803. PMID: 18032378. doi:10.1074/jbc.M708419200
   PubMed Web of Science ®Google Scholar
• Collado M, Serrano M. The senescent side of tumor suppression. Cell Cycle. 2005;4(12):1722–1724. PMID: 16294043. doi:10.4161/cc.4.12.2260
   PubMed Web of Science ®Google Scholar
• Sartorius K, An P, Winkler C, et al. The epigenetic modulation of cancer and immune pathways in hepatitis B virus-associated hepatocellular carcinoma: the influence of HBx and miRNA dysregulation. Front Immunol. 2021;12:661204. PMID: 33995383 PMCID: PMC8117219. doi:10.3389/fimmu.2021.661204
   PubMed Web of Science ®Google Scholar
• Pollicino T, Cacciola I, Saffioti F, Raimondo G. Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications. J Hepatol. 2014;61(2):408–417. PMID: 24801416. doi:10.1016/j.jhep.2014.04.041
   PubMed Web of Science ®Google Scholar
• Choi SH, Jeong SH, Hwang SB. Large hepatitis delta antigen modulates transforming growth factor-beta signaling cascades: implication of hepatitis delta virus-induced liver fibrosis. Gastroenterology. 2007;132(1):343–357. PMID: 17241884. doi:10.1053/j.gastro.2006.10.038
   PubMed Web of Science ®Google Scholar
• Hess J, Angel P, Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci. 2004;117(Pt25):5965–5973. PMID: 15564374. doi:10.1242/jcs.01589
   PubMedGoogle Scholar
• Goto T, Kato N, Yoshida H, et al. Synergistic activation of the serum response element-dependent pathway by hepatitis B virus x protein and large-isoform hepatitis delta antigen. J Infect Dis. 2003;187(5):820–828. PMID: 12599056. doi:10.1086/368389
   PubMed Web of Science ®Google Scholar
• Williams V, Brichler S, Khan E, et al. Large hepatitis delta antigen activates STAT-3 and NF-κB via oxidative stress. J Viral Hepat. 2012;19(10):744–753. PMID: 22967106. doi:10.1111/j.1365-2893.2012.01597.x
   PubMed Web of Science ®Google Scholar
• Park CY, Oh SH, Kang SM, Lim YS, Hwang SB. Hepatitis delta virus large antigen sensitizes to TNF-alpha-induced NF-kappaB signaling. Mol Cells. 2009;28(1):49–55. PMID: 19711042. doi:10.1007/s10059-009-0100-5
   PubMed Web of Science ®Google Scholar
• Benegiamo G, Vinciguerra M, Guarnieri V, Niro GA, Andriulli A, Pazienza V. Hepatitis delta virus induces specific DNA methylation processes in Huh-7 liver cancer cells. FEBS Lett. 2013;587(9):1424–1428. PMID: 23523924. doi:10.1016/j.febslet.2013.03.021
   PubMed Web of Science ®Google Scholar
• Liao FT, Lee YJ, Ko JL, Tsai CC, Tseng CJ, Sheu GT. Hepatitis delta virus epigenetically enhances clusterin expression via histone acetylation in human hepatocellular carcinoma cells. J Gen Virol. 2009;90(Pt 5):1124–1134. PMID: 19264665. doi:10.1099/vir.0.007211-0
   PubMedGoogle Scholar
• Trougakos IP, Gonos ES. Regulation of clusterin/apolipoprotein J, a functional homologue to the small heat shock proteins, by oxidative stress in ageing and age-related diseases. Free Radic Res. 2006;40(12):1324–1334. PMID: 17090421. doi:10.1080/10715760600902310
   PubMed Web of Science ®Google Scholar
• Chen M, Du D, Zheng W, et al. Small hepatitis delta antigen selectively binds to target mRNA in hepatic cells: a potential mechanism by which hepatitis D virus downregulates glutathione S-transferase P1 and induces liver injury and hepatocarcinogenesis. Biochem Cell Biol. 2019;97(2):130–139. PMID: 30153423. doi:10.1139/bcb-2017-0321
   PubMedGoogle Scholar
• Yu Z, Ma X, Zhang W, et al. Microarray data mining and preliminary bioinformatics analysis of hepatitis D virus-associated hepatocellular carcinoma. Biomed Res Int. 2021;2021:1093702. PMID: 33564675 PMCID: PMC7867452. doi:10.1155/2021/1093702
   PubMed Web of Science ®Google Scholar
• Abbas Z, Abbas M, Abbas S, Shazi L. Hepatitis D and hepatocellular carcinoma. World J Hepatol. 2015;7(5):777–786. PMID: 25914778 PMCID: PMC4404383. doi:10.4254/wjh.v7.i5.777
   PubMedGoogle Scholar
• Jang TY, Wei YJ, Liu TW, et al. Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. Sci Rep. 2021;11(1):8184. PMID: 33854160 PMCID: PMC8047028. doi:10.1038/s41598-021-87679-w
   PubMed Web of Science ®Google Scholar
• Russo FP, Zanetto A, Pinto E, et al. Hepatocellular carcinoma in chronic viral hepatitis: where do we stand? Int J Mol Sci. 2022;23(1):500. PMID: 35008926 PMCID: PMC8745141. doi:10.3390/ijms23010500
   PubMed Web of Science ®Google Scholar
• Philips CA, Rajesh S, Nair DC, Ahamed R, Abduljaleel JK, Augustine P. Hepatocellular carcinoma in 2021: an exhaustive update. Cureus. 2021;13(11):e19274. PMID: 34754704 PMCID: PMC8569837. doi:10.7759/cureus.19274
   PubMed Web of Science ®Google Scholar
• Botelho-Souza LF, Vasconcelos MPA, Dos Santos AO, Salcedo JMV, Vieira DS. Hepatitis delta: virological and clinical aspects. Virol J. 2017;14(1):177. PMID: 28903779 PMCID: PMC5597996. doi:10.1186/s12985-017-0845-y
   PubMedGoogle Scholar
• Papatheodoridis A, Papatheodoridis G. Hepatocellular carcinoma: the virus or the liver? Liver Int. 2022. PMID: 35319167. doi:10.1111/liv.15253
   Google Scholar
• Abbas Z, Qureshi M, Hamid S, Jafri W. Hepatocellular carcinoma in hepatitis D: does it differ from hepatitis B monoinfection? Saudi J Gastroenterol. 2012;18(1):18–22. PMID: 22249087 PMCID: PMC3271688. doi:10.4103/1319-3767.91731
   PubMed Web of Science ®Google Scholar
• Stella L, Santopaolo F, Gasbarrini A, Pompili M, Ponziani FR. Viral hepatitis and hepatocellular carcinoma: from molecular pathways to the role of clinical surveillance and antiviral treatment. World J Gastroenterol. 2022;28(21):2251–2281. PMID: 35800182 PMCID: PMC9185215. doi:10.3748/wjg.v28.i21.2251
   PubMed Web of Science ®Google Scholar
• Lin C-L, Kao J-H. Review article: the prevention of hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther. 2018;1:1–10. doi:10.1111/apt.14683
   Google Scholar
• Chen DS, Hsu NHM, Sung JL, et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA. 1987;257:2597–2603. doi:10.1001/jama.1987.03390190075023
   PubMed Web of Science ®Google Scholar
• Stevens CE, Toy P, Kamili S, et al. Eradicating hepatitis B virus: the critical role of preventing perinatal transmission. Biologicals. 2017;50:3–19. doi:10.1016/j.biologicals.2017.08.008
   PubMed Web of Science ®Google Scholar
• Wu CY, Lin JT, Ho HJ, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology. 2014;147:143–151. doi:10.1053/j.gastro.2014.03.048
   PubMed Web of Science ®Google Scholar
• Ferenci P, Reiberger T, Jachs M. Treatment of chronic hepatitis D with bulevirtide-A fight against two foes-an update. Cells. 2022;11(22):3531. PMID: 36428959 PMCID: PMC9688382. doi:10.3390/cells11223531
   PubMed Web of Science ®Google Scholar
• Wu JC, Huang YH, Chau GY, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol. 2009;51:890–897. doi:10.1016/j.jhep.2009.07.009
   PubMed Web of Science ®Google Scholar
• Sasaki K, Shindoh J, Nishioka Y, et al. Impact of viral etiology on postoperative de novo recurrence after hepatectomy for hepatocellular carcinoma in cirrhotic patients. J Gastrointest Surg. 2017;21:487–495. doi:10.1007/s11605-016-3344-3
   PubMed Web of Science ®Google Scholar